PharmaCyte Biotech, Inc.

- 14 DEC 2020
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
LAGUNA HILLS, CA, December 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional physical parameter testing of its CypCaps® product for pancreatic cancer, in line with the recommendations
Read more →
- Posted in
- News
- 02 DEC 2020
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
LAGUNA HILLS, CA, December 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration
Read more →
- Posted in
- News
- 04 NOV 2020
PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND).
Read more →
- Posted in
- News
- 02 OCT 2020
PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA
LAGUNA HILLS, CA, October 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the company’s submitted Investigational New Drug
Read more →
- Posted in
- News
- 23 SEP 2020
PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period
LAGUNA HILLS, CA, September 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it continues to engage with the U.S. Food and Drug Administration (FDA) during its 30-day comment period regarding
Read more →
- Posted in
- News
- 14 SEP 2020
PharmaCyte Biotech Successfully Completes Six-Month Stability Study
LAGUNA HILLS, CA, September 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the six-month product stability testing that is required by the U.S. Food and Drug
Read more →
- Posted in
- News
- 08 SEP 2020
PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test
LAGUNA HILLS, CA, September 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the second Container Closure Integrity (CCI) test that is required by the U.S. Food
Read more →
- Posted in
- News
- 02 SEP 2020
PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer
LAGUNA HILLS, CA, September 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for
Read more →
- Posted in
- News
- 10 AUG 2020
PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
LAGUNA HILLS, CA, August 10, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed José L. Iglesias M.D. as Consulting Chief
Read more →
- Posted in
- News
- 05 AUG 2020
FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy
LAGUNA HILLS, CA, August 5, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has
Read more →
- Posted in
- News

Press Releases